B & T Capital Management DBA Alpha Capital Management - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 479 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.1%.

Quarter-by-quarter ownership
B & T Capital Management DBA Alpha Capital Management ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q2 2024$1,978,711
-34.4%
36,636
-17.2%
0.38%
-34.5%
Q1 2024$3,015,808
+7.7%
44,246
-1.1%
0.59%
+1.6%
Q4 2023$2,800,599
+33.7%
44,738
-3.1%
0.58%
+18.2%
Q3 2023$2,094,704
+56.4%
46,149
+40.1%
0.49%
+46.3%
Q2 2023$1,339,0520.0%32,9410.0%0.34%0.0%
Q1 2023$1,339,0520.0%32,9410.0%0.34%0.0%
Q4 2022$1,339,052
-32.0%
32,941
+9.4%
0.34%
-35.8%
Q3 2022$1,968,000
+20.4%
30,118
+11.9%
0.52%
+16.8%
Q2 2022$1,635,000
+11.7%
26,905
+15.4%
0.45%
+40.6%
Q1 2022$1,464,000
-14.0%
23,324
+3.8%
0.32%
-15.4%
Q4 2021$1,703,000
-38.9%
22,472
-9.7%
0.38%
-43.1%
Q3 2021$2,786,000
-32.4%
24,891
-2.2%
0.66%
-31.7%
Q2 2021$4,122,000
+305.7%
25,460
+205.2%
0.97%
+273.7%
Q1 2021$1,016,000
+28.1%
8,342
+61.1%
0.26%
+29.5%
Q4 2020$793,0005,1780.20%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$37,781,00020.21%
Ariose Capital Management Ltd 37,900$2,872,0006.78%
EcoR1 Capital, LLC 1,077,483$81,652,0002.60%
NEA Management Company, LLC 1,590,002$120,490,0002.44%
ARK Investment Management 9,087,868$688,679,0002.08%
NIA IMPACT ADVISORS, LLC 62,609$3,876,0002.06%
Deuterium Capital Management, LLC 18,000$1,364,0002.02%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 108,200$8,192,0001.82%
PLUSTICK MANAGEMENT LLC 50,000$3,789,0001.76%
Nikko Asset Management Americas, Inc. 4,319,471$330,526,0001.74%
View complete list of CRISPR THERAPEUTICS AG shareholders